No products in the cart.
CIMAVAX-EGF®
The stated pricing is the box price. There are 4 pieces in 1 box.
CIMAvax-EGF is a lung cancer treatment that was developed in Cuba. It is a type of immunotherapy that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Our trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced non-small cell lung cancer (NSCLC).
Another trial is testing CIMAvax-EGF for the prevention of lung cancer in patients who are at high risk or to prevent recurrence of lung cancer.
Description
The CIMAvax – EGF® vaccine is a scientific result of Cuban biotechnology, of great international prestige, with excellent benefits in Cuban patients and in many other countries. It is a very safe vaccine that improves survival.
The treatment requires admission with a companion. It is administered intra muscular. It consists of an induction phase that begins with the administration of the first five doses during 14 days and a maintenance phase that includes re-immunizations every 28 days, which will be maintained until the patient’s condition allows it.
In the Cuban oncology services that offer this program, the patient is evaluated by multidisciplinary teams (nationally certified and internationally endorsed) made up of internists, radiologists, pathologists, hematologists, surgeons, among others, presided over by a clinical oncologist. These specialists are responsible for establishing, according to the diagnosis and stage of the cancer, the personalized treatment.
You must be logged in to post a review.
Reviews
There are no reviews yet.